Thus, it may be crucial to choose and evaluate compounds based on the bottom of the ligand pocket in the current ETB-Gi structure (Figure 2B) to develop small molecule ETB agonists for neuroprotection and cancer therapy. This evidence concerns the gene GNAI1 and cancer.